Intrapleural or Intraperitoneal Lobaplatin for Treatment of Patients with Malignant Pleural Effusion or Ascites

Huang, Xin-En; Wei, Guo-Li; Huo, Jie-Ge; Wang, Xiaoning; Lu, Yen‐Shen; Wu, Xueyan; Liu, Jin; Xiang, Jin; Feng, Jifeng

doi:10.7314/apjcp.2013.14.4.2611

Cited by 47 publications

(30 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this way, LBP has shown good antitumour activity. In vivo, LBP remains good stability and low toxicity, some tumors resistanted to cisplatin are still sensitive to LBP.LBP has activity in a wider range of tumour types (McKeage, 2001;Wu, et al, 2010;Deng et al, 2013;Huang et al, 2013). LBP has been approved good inhibitory effect for the hepatocellular carcinoma cell lines (SMMC-27721, HepG2 and Bel2-7402) in the experiments in vitro (Qian et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

Lobaplatin Combined Floxuridine/Pirarubicin-based Transcatheter Hepatic Arterial Chemoembolization for Unresectable Primary Hepatocellular Carcinoma

Zhao

Wang²,

Wang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Lobaplatin Combined Floxuridine/Pirarubicin-based Transcatheter Hepatic Arterial Chemoembolization for Unresectable Primary Hepatocellular Carcinoma

Zhao

Wang²,

Wang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Its use, however, is limited by sometimes severe organ toxicity, especially neuro-and nephrotoxicity. Carboplatin shows a favorable spectrum of toxicity, with reversible myelosuppression being the dose-limiting toxicity (Deng et al, 2013;Huang et al, 2013;Peng et al, 2014;Wang et al, 2014;Wu et al, 2014;Zhao et al, 2014). Especially in ovarian cancer, carboplatin appears to have equivalent activity to cisplatin.…”

Section: Discussionmentioning

confidence: 99%

Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells

Sun¹,

Lou²,

Sui³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Lobaplatin, one of the third -generation platinum compounds, has shown encouraging anticancer activity in a variety of tumor types. However, the efficacy of lobaplatin in ovarian cancer has not been systemically evaluated. In this study, lobaplatin as a single agent and in combination with taxanes was investigated in -vitro and in an in vitro model of ovarian carcinoma. Using the sulforhodamine B (SRB) assay, the cytotoxic effects of lobaplatin alone and in combination with taxanes were compared with cisplatin and carboplatin in seven ovarian cancer cell lines. In addition, in -vitro antitumor activities were evaluated with cisplatin -sensitive and cisplatin -resistant human ovarian cancer xenografts in nude mice. The cytotoxicity of lobaplatin was similar to or higher than that of cisplatin and carboplatin, with IC 50 values from 0.9 to 13.8 µmol/L in a variety of ovarian cancer cells. The combination of lobaplatin with docetaxel yielded enhanced cytotoxic activity in vitro. In addition, in platinum -sensitive ovarian cancer xenografts, lobaplatin alone showed similar antitumor activity to cisplatin and carboplatin. Furthermore, lobaplatin alone or in combination with docetaxel exhibited significant activity in platinum -resistant ovarian cancer xenografts. These results indicate that the use of lobaplatin alone or in combination with docetaxel might be a rational and novel therapeutic strategy for ovarian cancer. Further clinical development of lobaplatin is clearly warranted.

show abstract

“…The above hypothesis test was a two-sided test; P<0.05 was considered as statistically significant. We have enough experience in conducting medical researches, and have published some results elsewhere Yan et al, 2011;Zhang et al, 2011;Gong et al, 2012;Liu et al, 2012;Gu et al, 2013;Shu et al, 2012;Xu et al, 2012;Xu et al, 2012;Yu et al, 2012;Zhang et al, 2012;Chen et al, 2013;Dai et al, 2013;Deng et al, 2013;Huang et al, 2013;Lu et al, 2013;Sun et al, 2013;Wei et al, 2013;Wu et al, 2013;Yang et al, 2013;.…”

Section: Statistical Methods and Research Experiencementioning

confidence: 99%

CXCL12-CXCR4 Promotes Proliferation and Invasion of Pancreatic Cancer Cells

Shen

Zheng²,

Lu³

et al. 2013

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

Objective: CXCL12 exerts a wide variety of chemotactic effects on cells. Evidence indicates that CXCL12, in conjunction with its receptor, CXCR4, promotes invasion and metastasis of tumor cells. Our objective was to explore whether the CXCL12-CXCR4 biological axis might influence biological behavior of pancreatic cancer cells. Methods: Miapaca-2 human pancreatic cancer cells were cultured under three different conditions: normal medium (control), medium + recombinant CXCL12 (CXCL12 group), or medium + CXCR4-inhibitor AMD3100 (AMD3100 group). RT-PCR was applied to detect mRNA expression levels of CXCL12, CXCR4, matrix metalloproteinase 2 (MMP-2), MMP-9, and human urokinase plasminogen activator (uPA). Additionally, cell proliferation and invasion were performed using CCK-8 colorimetry and transwell invasion assays, respectively. Results: CXCL12 was not expressed in Miapaca-2 cells, but CXCR4 was detected, indicating that these cells are capable of receiving signals from CXCL12. Expression of extracellular matrix-degrading enzymes MMP-2, MMP-9, and uPA was upregulated in cells exposed to exogenous CXCL12 (P<0.05). Additionally, both proliferation and invasion of pancreatic cancer cells were enhanced in the presence of exogenous CXCL12, but AMD3100 intervention effectively inhibited these processes (P<0.05). Conclusions: The CXCL12-CXCR4 biological axis plays an important role in promoting proliferation and invasion of pancreatic cancer cells.

show abstract

Intrapleural or Intraperitoneal Lobaplatin for Treatment of Patients with Malignant Pleural Effusion or Ascites

Cited by 47 publications

References 36 publications

Lobaplatin Combined Floxuridine/Pirarubicin-based Transcatheter Hepatic Arterial Chemoembolization for Unresectable Primary Hepatocellular Carcinoma

Lobaplatin Combined Floxuridine/Pirarubicin-based Transcatheter Hepatic Arterial Chemoembolization for Unresectable Primary Hepatocellular Carcinoma

Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells

CXCL12-CXCR4 Promotes Proliferation and Invasion of Pancreatic Cancer Cells

Contact Info

Product

Resources

About